Orion Oyj ADR (ORINY)

OTC Markets
Currency in USD
25.49
+0.05(+0.20%)
Closed
ORINY Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
Unusual trading volume
Fair Value
Day's Range
25.3825.49
52 wk Range
17.5028.55
Key Statistics
Edit
Prev. Close
25.49
Open
25.38
Day's Range
25.38-25.49
52 wk Range
17.5-28.55
Volume
2.49K
Average Volume (3m)
932
1-Year Change
12.39%
Book Value / Share
7.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORINY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Orion Oyj ADR Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Employees
3867

Compare ORINY to Peers and Sector

Metrics to compare
ORINY
Peers
Sector
Relationship
P/E Ratio
20.7x17.6x−0.6x
PEG Ratio
0.230.100.00
Price/Book
7.4x2.5x2.6x
Price / LTM Sales
4.8x2.3x3.1x
Upside (Analyst Target)
-25.9%54.6%
Fair Value Upside
Unlock10.4%7.7%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.36
Dividend Yield
0.91%
Industry Median 1.73%
Annualised payout
0.2332
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Orion ADR (ORINY) Stock Price Today?

The Orion ADR stock price today is 25.49

What Stock Exchange Does Orion ADR Trade On?

Orion ADR is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Orion ADR?

The stock symbol for Orion ADR is "ORINY."

Does Orion ADR Pay Dividends? What’s The Current Dividend Yield?

The Orion ADR dividend yield is 0.91%.

What Is the Orion ADR Market Cap?

As of today, Orion ADR market cap is 7.17B.

What is Orion ADR Earnings Per Share?

The Orion ADR EPS is 2.36.

From a Technical Analysis Perspective, Is ORINY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.